Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression.
The heterogeneity of prostate cancers is evident at earlier stages, and has led to rigorous …

Most of the prostate cancers (PCa) in advanced stage will progress to castration-resistant
prostate cancer (CRPC). Within CRPC group, 50-70% of the patients will develop bone …

Cancer stem-like cells (CSCs) are rare subpopulations of cancer cells that are reported to be
responsible for cancer resistance and metastasis associated with conventional cancer …

Androgen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches
for AR inactivation include chemical castration, inhibition of androgen synthesis and AR …

Benign Prostate hyperplasia (BPH) and prostate cancer (PCa) are the most common
prostatic disorders affecting elderly men. Multiple factors including hormonal imbalance …

Prostate cancer (PCa) is one of the most common causes of male cancer-related death in
Western nations. The cellular response to androgens is mediated via the androgen receptor …

Abstract Background Prostate cancer (PCa) is one of the most frequently diagnosed tumors
in men. In general, therapies for localized PCa are curative. However, treatment of advanced …

Although androgen deprivation therapy (ADT) is a standard treatment for metastatic prostate
cancer, this disease inevitably recurs and progresses to ADT‐resistant stage after this …

While chromosomal translocations have a fundamental role in the development of several
human leukaemias, their role in solid tumour development has been somewhat more …

The development of novel therapies such as abiraterone acetate and sipuleucel-T has
improved the outlook for patients with advanced-stage and castration-resistant prostate …